1-methyl-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one | 40423-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 1-methyl-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one
• 英文别名: 1-methyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one；1-methyl-1H-imidazo[4,5-c]pyridin-2(3H)-one；1-Methylimidazo<4,5-c>-pyridin-2-on；1-Methylimidazo-<4,5-c>-2-pyridon；1-methyl-1,3-dihydro-imidazo[4,5-c]pyridin-2-one；1-methyl-2(3H)-oxo-imidazo-[4,5-c]pyridine；1-methyl-1H,2H,3H-imidazo[4,5-c]pyridin-2-one；1-methyl-3H-imidazo[4,5-c]pyridin-2-one
• CAS: 40423-52-7
• 化学式: C₇H₇N₃O
• mdl: MFCD18258912
• 分子量: 149.152
• InChiKey: YMJWXQIUTGOQMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methyl-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one 在 sodium hydroxide 、 硫酸 、 硝酸 作用下， 以 水 为溶剂， 反应 4.0h， 生成 4-propoxy-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one
  参考文献：
  名称：

  咪唑并[4,5-c]吡啶-2-酮的4-硝基衍生物的合成及一些反应

  摘要：

  DOI：

  10.1007/bf00515430
• 作为产物：
  描述：

  1-(3-iodopyridin-4-yl)-1-methylurea 在 copper(l) iodide 、 1,10-菲罗啉 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 以66 %的产率得到1-methyl-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one
  参考文献：
  名称：

  可扩展的铜催化从碘代吡啶基脲制备咪唑并吡啶酮

  摘要：

  描述了咪唑并吡啶酮的有效铜催化结构。从碘代吡啶基脲开始，Ullmann 偶联以高产率提供咪唑并吡啶酮。以 473 千克的规模描述了通过此过程进行的制造；基板的范围和限制也有详细说明。

  DOI：

  10.1002/jhet.4592

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• 3-fused pyridiniummethyl cephalosporins
  申请人：Cheil Foods & Chemicals, Inc.

  公开号：US05281589A1

  公开（公告）日：1994-01-25

  Novel semi-synthetic cephalosporin derivatives having a fused pyridiniummethyl at 3-position of the cephem nucleus, pharmaceutically acceptable salts, physiologically hydrolizable esters or solvates thereof are disclosed. Also disclosed is a process for preparing the cephalosporin derivatives which comprises introducing a fused pyridiniummethyl substituent at 3-position of 7-.beta.-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-ca rboxylic acid derivatives. The compounds of the present invention show potent antibacterial activities and a broad spectrum against both gram-positive and gram-negative bacteria.

  新型半合成头孢菌素衍生物，在头孢菌素核的3位具有融合的吡啶甲基，以及其药用可接受的盐、生理可水解的酯或溶剂合物。还公开了一种制备头孢菌素衍生物的方法，包括在7-β-[(Z)-2-(2-氨基噻唑-4-基)-2-甲氧基亚胺基乙酰氨基]-3-头孢菌素羧酸衍生物的3位引入融合的吡啶甲基取代基。本发明的化合物表现出强大的抗菌活性，并对革兰氏阳性和革兰氏阴性细菌都具有广谱活性。
• Spirolactam Bicyclic CGRP Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090325991A1

  公开（公告）日：2009-12-31

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• Bicyclic spirohydantoin CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08071771B2

  公开（公告）日：2011-12-06

  Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2 and R6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B，E1，E2，E3，E4，E5，G1，G2和R6如本文所述），它们是CGRP受体的拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Spirolactam bicyclic CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08071772B2

  公开（公告）日：2011-12-06

  Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式I的化合物：（其中变量A1、A2、A3、A4、A5、A6、A7、B、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述），其为CGRP受体拮抗剂，并且在治疗或预防CGRP参与的疾病，如偏头痛方面有用。本发明还涉及包含这些化合物的制药组合物，以及在预防或治疗CGRP参与的疾病方面使用这些化合物和组合物。